TY - JOUR
T1 - Removal of basiliximab by plasmapheresis.
AU - Okechukwu, C. N.
AU - Meier-Kriesche, H. U.
AU - Armstrong, D.
AU - Campbell, D.
AU - Gerbeau, C.
AU - Kaplan, B.
PY - 2001/1
Y1 - 2001/1
N2 - Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.
AB - Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.
UR - http://www.scopus.com/inward/record.url?scp=0035220454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035220454&partnerID=8YFLogxK
U2 - 10.1053/ajkd.2001.20636
DO - 10.1053/ajkd.2001.20636
M3 - Article
C2 - 11136200
AN - SCOPUS:0035220454
SN - 0272-6386
VL - 37
SP - E11
JO - American journal of kidney diseases : the official journal of the National Kidney Foundation
JF - American journal of kidney diseases : the official journal of the National Kidney Foundation
IS - 1
ER -